IL287536A - Compositions and methods for use of cannabinoids for neuroprotection - Google Patents

Compositions and methods for use of cannabinoids for neuroprotection

Info

Publication number
IL287536A
IL287536A IL287536A IL28753621A IL287536A IL 287536 A IL287536 A IL 287536A IL 287536 A IL287536 A IL 287536A IL 28753621 A IL28753621 A IL 28753621A IL 287536 A IL287536 A IL 287536A
Authority
IL
Israel
Prior art keywords
cannabinoids
neuroprotection
compositions
methods
Prior art date
Application number
IL287536A
Other languages
Hebrew (he)
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Original Assignee
Inmed Pharmaceuticals Inc
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc, Eric Hsu, Ujendra Kumar, Rishi Kumar Somvanshi, Shenglong Zou filed Critical Inmed Pharmaceuticals Inc
Publication of IL287536A publication Critical patent/IL287536A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
IL287536A 2019-04-24 2021-10-24 Compositions and methods for use of cannabinoids for neuroprotection IL287536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
IL287536A true IL287536A (en) 2021-12-01

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287536A IL287536A (en) 2019-04-24 2021-10-24 Compositions and methods for use of cannabinoids for neuroprotection

Country Status (11)

Country Link
US (1) US20230043428A1 (en)
EP (1) EP3958856A4 (en)
JP (1) JP2022530471A (en)
KR (1) KR20220080045A (en)
CN (1) CN114007603A (en)
AU (1) AU2020261515A1 (en)
CA (1) CA3134764A1 (en)
IL (1) IL287536A (en)
MX (1) MX2021012960A (en)
SG (1) SG11202111809XA (en)
WO (1) WO2020215164A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (en) * 2022-08-09 2022-09-06 昆药集团股份有限公司 Pharmaceutical composition with optic nerve protection effect and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7225103B2 (en) * 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド Cannabinoid-containing complex mixtures for treating neurodegenerative diseases
CA3062904A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Also Published As

Publication number Publication date
EP3958856A4 (en) 2023-01-25
JP2022530471A (en) 2022-06-29
SG11202111809XA (en) 2021-11-29
CN114007603A (en) 2022-02-01
WO2020215164A1 (en) 2020-10-29
KR20220080045A (en) 2022-06-14
MX2021012960A (en) 2022-01-04
CA3134764A1 (en) 2020-10-29
US20230043428A1 (en) 2023-02-09
EP3958856A1 (en) 2022-03-02
AU2020261515A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
GB2597163B (en) Cannabinoid compositions and methods of using
EP3775203A4 (en) Oligonucleotide compositions and methods of use thereof
EP3790596A4 (en) Oligonucleotide compositions and methods of use thereof
EP3704254A4 (en) Cas12c compositions and methods of use
EP3893917A4 (en) Il-15 compositions and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
EP3551747A4 (en) Compositions and methods for maturation of oocytesin vitro
EP3600372A4 (en) Synthekine compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
GB202105087D0 (en) Microbial compositions and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL283850A (en) Cannabis compositions and methods
GB2597170B (en) Diluents for compositions of cannabinoids and uses thereof
IL275739A (en) Compositions for cryopreservation and methods of use thereof
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3285755A4 (en) Compositions and methods for neuroprotection and treatment of neurodegeneration
IL283950A (en) Methods and compositions for producing cannabinoids
IL287536A (en) Compositions and methods for use of cannabinoids for neuroprotection
EP3426238A4 (en) Curcumin-based compositions&methods of use thereof
EP3920904A4 (en) Compositions comprising cannabinoids and methods of use thereof
EP4054514A4 (en) Compositions containing fenchols and methods of use
IL276680B1 (en) Silica fiber compositions and methods of use
EP3823451A4 (en) Extended and continuous release compositions for plant health and methods of use
EP3843555A4 (en) Anthocyanin-based colorant compositions and methods of use thereof